Press Releases

Date Title and Summary
Sep 18, 2023

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

CORAL GABLES, Fla. , Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that
Aug 16, 2023

Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer

Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer CORAL GABLES, Fla. , Aug. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,
Aug 14, 2023

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

CORAL GABLES, Fla. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare
Aug 09, 2023

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

Achieved Record Q2 2023 Total Net Revenues of $99.6 Million Achieved FIRDAPSE ® 2023 Second Quarter Net Revenues of $64.9 Million , a 22% Increase YOY Achieved 2023 Second Quarter GAAP EPS Diluted of $0.33 Compared to $0.20 for Q2 2022 Achieved 2023 Second Quarter Non-GAAP EPS Diluted of $0.53
Jul 25, 2023

Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End

Mr. McEnany will Continue to Serve as Catalyst's Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search CORAL GABLES, Fla. , July 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
Jul 24, 2023

Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023

The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET CORAL GABLES, Fla. , July 24, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and
Jul 19, 2023

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters Catalyst's Rare Neuroscience Portfolio Granted FDA Fast Track, Orphan Drug Designation, and a PDUFA Action
Jun 20, 2023

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023 ) for the Treatment of Duchenne Muscular Dystrophy, a Rare Neuromuscular Disease FDA has Granted Fast Track and Orphan Drug Designation for Vamorolone to Treat Duchenne Muscular Dystrophy Catalyst Expects to Launch
Jun 01, 2023

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE ® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million , an Increase of 17% YoY Forecasts FYCOMPA ® 2023 Net Product Revenue of Approximately $130 Million for 11 Months
May 30, 2023

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

CORAL GABLES, Fla. , May 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today

Displaying 1 - 10 of 23